 |
|
|
| |
Final SVR24 Data from the Phase 3 C-EDGE Treatment-Naïve Study of Elbasvir/Grazoprevir in Patients With Chronic HCV Genotype 1, 4,
or 6 Infection
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Zeuzem S1; Ghalib R2; Reddy KR3; Pockros PJ4; Ben-Ari Z5; Zhao Y6; Brown DD6; Wan S6; DiNubile MJ6; Robertson MN6; Wahl J6; Barr E6; Butterton JR6; Martin E6
1Goethe University Hospital, Frankfurt, Germany; 2Texas Clinical Research Institute, Arlington, TX, USA; 3University of Pennsylvania, Philadelphia, PA, USA; 4Scripps Translational Science Institute, La Jolla, CA, USA; 5Sheba Medical Center, Ramat Gan, Israel; 6Merck & Co., Inc., Kenilworth, NJ, USA
AASLD: The Combination of Elbasvir and Grazoprevir ± RBV Is Highly Effective for the Treatment of GT1a-Infected Patients - (11/17/15) 16 weeks with RAVs
hepDART: Optimizing Outcomes in HCV Patients: Elbasvir/Grazoprevir: kidney disease/IDUs/resistance (01/04/16)
EASL: C-EDGE: HEAD 2 HEAD - Efficacy and Safety of Elbasvir/Grazoprevir versus Sofosbuvir /Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and Prior PR Treatment Failure Subjects with Chronic HCV GT1 or 4 Infection - (04/15/16)
EASL: High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16)
|
| |
|
|
|
|
|
